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        Introduction 
  Aberrant activation of the class I phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway has been widely implicated in a variety of 
cancers, and the three Akt isoforms represent attractive cancer 
therapeutic targets (  Samuels and Ericson, 2006  ;   Stambolic and 
Woodgett, 2006  ). Genetic ablations of   Akt   genes in mice have 
revealed both distinct and overlapping functions of each iso-
form in normal physiology ( Chen et al., 2001 ;  Cho et al., 2001a , b ; 
  Peng et al., 2003  ;   Easton et al., 2005  ;   Tschopp et al., 2005  ;   Yang 
et al., 2005  ) and tumor initiation (  Chen et al., 2006  ;   Skeen et al., 
2006  ;   Ju et al., 2007  ;   Maroulakou et al., 2007  ). The relative 
contribution of the Akt isoforms in maintaining human tumor 
growth remains elusive, however. Human cancers usually co-
express two or all three Akt isoforms, and amplifi  cation or hyper-
activation of each isoform has been documented in different 
types of cancers (  Stahl et al., 2004  ;   Altomare and Testa, 2005  ). 
Mounting evidence suggests that Akt isoforms may be differen-
tially regulated depending on the external stimuli and the tissue 
studied and may regulate distinct aspects of cellular processes 
in a cell- and tissue-specifi  c manner (  Kim et al., 2001  ;   Tanno et al., 
2001  ;   Dufour et al., 2004  ;   Irie et al., 2005  ;   Samuels et al., 2005  ; 
  Yoeli-Lerner et al., 2005  ). 
  Akt is well known for its antiapoptotic activity when over-
expressed under stress conditions (  Amaravadi and Thompson, 
2005  ). However, inhibiting components of the PI3K  –  Akt pathway 
A
lthough Akt is known as a survival kinase, 
inhibitors of the phosphatidylinositol 3-kinase 
(PI3K)  –  Akt pathway do not always induce sub-
stantial apoptosis. We show that silencing Akt1 alone, 
or any combination of Akt isoforms, can suppress the 
growth of tumors established from phosphatase and ten-
sin homologue  –  null human cancer cells. Although these 
ﬁ  ndings indicate that Akt is essential for tumor mainte-
nance, most tumors eventually rebound. Akt knockdown 
or inactivation with small molecule inhibitors did not in-
duce signiﬁ  cant apoptosis but rather markedly increased 
autophagy. Further treatment with the lysosomotropic 
agent chloroquine caused accumulation of abnormal auto-
phagolysosomes and reactive oxygen species, leading to 
accelerated cell death in vitro and complete tumor remis-
sion in vivo. Cell death was also promoted when Akt in-
hibition was combined with the vacuolar H 
+    –  adenosine 
triphosphatase inhibitor baﬁ  lomycin A1 or with cathepsin 
inhibition. These results suggest that blocking lysosomal 
degradation can be detrimental to cancer cell survival when 
autophagy is activated, providing rationale for a new ther-
apeutic approach to enhancing the anticancer efﬁ  cacy of 
PI3K  –  Akt pathway inhibition.
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  <  10% of total Akt, whereas in U87MG cells, all three Akt pro-
teins are expressed at equivalent levels (Fig. S1 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). 
Stable clones of PC3 and U87MG cells were generated harbor-
ing inducible shRNA constructs targeting all possible single 
and combined Akt isoforms (Table S1). Each Akt-targeting 
shRNA (shAkt) caused     75  –  99% KD of the corresponding Akt 
mRNA and proteins upon doxycycline (Dox) induction (  Fig. 1 A  , 
Fig. S1 B, and Table S2). 
[ID]FIG1 [/ID]  Decreased steady-state phosphory-
lation of downstream targets PRAS40 and S6, up-regulation of 
p27 
Kip1  , and feedback stabilization of IRS1 were observed to 
varying degrees in response to the KDs, with the strongest ef-
fects observed in cells with all three Akt KDs (  Fig. 1 A  ). 
  We next examined the effect of Akt KDs on the ability of 
PC3 cells to maintain the growth of established tumors in vivo. 
Dox-induced KD of Akt2 (shAkt2) or Akt3 (shAkt3) alone did 
not result in signifi  cant inhibition of tumor growth (  Fig. 1 B   and 
Table S2). In contrast, two different shRNA constructs targeting 
Akt1 (shAkt1) both showed signifi  cant tumor growth inhibition, 
each in two out of three independent clones. Tumor growth re-
tardation or stasis was typically observed in these clones (  Fig. 1 B  , 
Fig. S1 H, and Table S2). Simultaneous KD of Akt1,2 (shAkt12) 
or Akt1,3 (shAkt13) also inhibited tumor growth, with almost 
all tumor growth halted and tumor regression observed in sev-
eral of the Dox-treated mice. Interestingly, KD of both Akt2 and 
Akt3 (shAkt23) also resulted in signifi  cant tumor growth in-
hibition, with no tumor volume doubling during the 2 wk of Dox 
treatment, suggesting that Akt1 activity alone is not suffi  cient to 
maintain optimal tumor growth. Finally, triple-Akt KD (shAkt123) 
most effectively inhibited tumor growth, with consistent tumor 
regression observed during the fi  rst 2 wk of treatment. Similar 
results were observed in U87MG cells, which express similar 
levels of the three Akt isoforms. Among the three single KDs, 
only shAkt1 showed signifi  cant tumor stasis, and tumor regres-
sion was again observed with triple-Akt KD (Fig. S1, C  –  F). 
Thus, KD of Akt1 alone can inhibit tumor growth in both PC3 
and U87MG xenografts, and this Akt1 dependency is not sim-
ply a total Akt dose effect. More pronounced tumor growth in-
hibition and regression, however, occurs in tumors with KD of 
all three Akt isoforms. 
  Akt KDs induced cell cycle delay without 
signiﬁ  cant apoptosis 
  Analysis of PC3 tumors with Akt KDs revealed a mild decrease 
in the proliferation marker Ki-67 and no signifi  cant increase in 
TUNEL-positive cells compared with control tumors (  Fig. 2 A  ). 
[ID]FIG2[/ID]  
The lack of apoptosis was also observed in PC3 cells cultured in 
vitro. Under 10% FBS, a mild increase in G0/G1 and a decrease 
in S phase was observed in cells expressing each shAkt con-
struct. Slightly increased accumulation of cells in the G2/M 
phase was also observed in cells expressing shRNA for Akt1 
alone and any combinations of two or three Akt isoforms, sug-
gesting a cell cycle delay in both DNA replication and mito-
sis in these cells. However, no signifi  cant sub-G1 population 
was observed with any of the KDs (Fig. S2, A and B, available 
at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). 
Additional experiments also failed to detect signifi  cant caspase 
often does not induce substantial apoptosis without additional 
proapoptotic insults. This is exemplifi  ed in a recent study where 
a dual PI3K/mammalian target of rapamycin (mTOR) inhibitor 
that effi  ciently inhibited phosphorylation of Akt blocked prolif-
eration of glioma xenografts without the induction of apoptosis 
(  Fan et al., 2006  ). However, the enhanced tumorigenesis stimu-
lated by a constitutively active Akt is linked to its ability to in-
hibit autophagy but not apoptosis in a recent study (  Degenhardt 
et al., 2006  ), raising the possibility that autophagy may also be 
an important mechanism underlying the response to therapeutic 
agents targeting the PI3K  –  Akt pathway. Autophagy is a cata-
bolic process characterized by the appearance of autophagic 
vacuoles (AVs) in the cytoplasm, leading to self-digestion of 
cytoplasmic organelles and other constituents in the lysosomal 
compartments. Although autophagy may be capable of ultimate 
cell killing when allowed to reach its limit, it is also thought to 
be a temporary survival mechanism under stress conditions, and 
inhibiting autophagy can either promote or inhibit cell death de-
pending on the conditions and agents used (  Lockshin and Zakeri, 
2004  ;   Kroemer and Jaattela, 2005  ;   Levine and Yuan, 2005  ; 
  Amaravadi et al., 2007  ). 
  In this study, we describe the use of inducible short hair-
pin RNAs (shRNAs) to specifi  cally and stably knock down each 
of the three individual Akt isoforms, both singly and in all pos-
sible combinations, in human cancer cells defi  cient for the tu-
mor suppressor phosphatase and tensin homologue (PTEN), a 
negative regulator of the PI3K  –  Akt pathway. This approach avoids 
the possible nonspecifi  c or side effects associated with systemic 
treatment of small molecule inhibitors, allowing us to evaluate 
the specifi  c contributions of the Akt proteins in proliferation, 
survival, and tumor maintenance both in vitro and in vivo. We show 
that silencing Akt1 alone can suppress tumor growth, whereas 
simultaneous knockdown (KD) of all three isoforms provides 
the most consistent and pronounced tumor growth inhibition. 
The tumor cells exhibit markedly increased autophagy as a ma-
jor response to reduced Akt activity, whereas classical apoptosis 
was not the prevailing response. Blocking lysosome function by 
lysosomotropic agents or cathepsin inhibition signifi  cantly in-
creased the sensitivity of tumor cells to Akt inhibition both in 
vitro and in vivo, suggesting a critical role for autolysosomal 
degradation in cell survival under Akt inhibition. 
  Results 
  Inducible shRNA KD of Akt isoforms 
inhibited the growth of PTEN-null human 
tumor xenografts in a dose- and isoform-
dependent manner 
  To determine the relative contribution of the three Akt isoforms 
in maintaining tumor growth, we used a tet-inducible shRNA 
KD method using a recently described retroviral vector system, 
pHUSH (a tet-inducible plasmid vector for H1 or U6 short hair-
pin;   Gray et al., 2005  ;   Hoefl  ich et al., 2006  ). We chose the 
PTEN-null human prostate cancer cell line PC3 and the glioma 
cell line U87MG (  Li et al., 1997  ). Both lines express all three 
Akt isoforms; in PC3 cells, Akt1 protein is expressed at approx-
imately two times the level of Akt2, with Akt3 contributing to 103  BLOCKING DEGRADATION KILLS AUTOPHAGIC CELLS   • Degtyarev et al. 
activation in response to Akt KDs in both PC3 and U87MG cells 
(unpublished data). To partially mimic the suboptimal growth con-
dition in the in vivo environment, we starved the cells of serum 
in culture and asked whether the cells became more sensitive 
to Akt KD. Indeed, complete serum starvation or reducing se-
rum to 0.5% resulted in markedly increased accumulation of 
cells in the G0/G1 phase. However, still no signifi  cant sub-G1 
peak was observed for at least 2 d in 0% FBS and 5 d in 0.5% 
FBS (  Fig. 2, B and C  ). 
  Akt KD promoted autophagy in PC3 
and U87MG cells 
  Because Akt has been shown to inhibit autophagy (  Arico et al., 
2001  ;   Degenhardt et al., 2006  ), we asked whether specifi  c KD 
of endogenous Akt could promote autophagy. Indeed, EM anal-
ysis revealed a signifi  cantly increased accumulation of AVs in 
both PC3 and U87MG cells induced to express shAkt123 (  Fig. 3, 
A and B  ; and Fig. S2 C). 
[ID]FIG3[/ID]  The accumulation of AV and acidic 
vesicular organelles (AVOs) was further confi  rmed by localiza-
tion of the autophagosome marker GFP-LC3, staining with an 
anti-LC3 antibody, and fl  uorescent dyes monodansylcadaverine 
(MDC) and acridine orange (AO;   Fig. 4 A  , Fig. S2, D  –  G, and 
not depicted). 
[ID]FIG4[/ID]  
  We examined xenograft tumors expressing shAkt by EM. 
The control GFP-targeting shRNA  –  expressing PC3 tumors 
consist of healthy looking cells connected by cell  –  cell junctions 
(  Fig. 3 C  , a). In contrast, cells in the shAkt123-expressing tu-
mors exhibit morphological signs of degeneration and loss of 
cell  –  cell contact after 10  –  15 d of Dox treatment (  Fig. 3 C  , b). 
Late AVs positive for human lysosome-associated membrane 
protein (LAMP)1 are found in degenerating tumor cells ( Fig. 3 C , 
b  –  d). Also, these cells often contain swollen mitochondria and 
dilated RER that are drastically disorganized, suggesting a con-
nection between energy metabolism, ER stress, and autoph-
agy. Chromatin clumping and fragmentation characteristic of 
typical apoptosis are rarely observed in the degenerating tumor 
cells; instead, some AV-containing cells exhibit mild pyknosis 
typical of cells undergoing autophagic degeneration (  Fig. 3 C  , 
b and d). 
  To determine whether AV accumulation occurred in tumor 
cells before morphological signs of degeneration, we examined 
U87MG tumors with either 5 d or 3 wk of Akt KD. In tumors 
expressing shAkt123 for 5 d, most cells showed similar gross 
morphology to vehicle-treated controls, but with an approxi-
mately twofold increase in the percent AV area (from 0.78% in 
the control tumors to 1.53% in Dox-treated tumors; P   <   0.05; 
  Fig. 3 C  , e  –  h). After 3 wk of Akt KD, U87MG tumors show signs 
of degeneration in many cells similar to PC3 tumors treated 
for 15 d (unpublished data). 
  Lysosomotropic agents accelerated cell 
death in PC3 cells with Akt KD 
  Despite the elevated levels of autophagy and mild cell cycle de-
lay, PC3 cells expressing shAkt123 can survive in culture for 
many passages under 10% FBS without appreciable increase 
in cell death. Even under reduced serum (0.5% FBS), there is 
only marginal decrease in viability over a prolonged period 
  Figure 1.       Inducible KD of Akt isoforms and their effect on xenograft 
tumor growth.   (A) Immunoblot analysis of Akt isoforms and various 
downstream proteins in stable PC3 clones expressing the inducible 
shRNA constructs. Each clone was induced to express the respective 
shRNAs with 1   μ  g/ml Dox grown under 10% FBS for 7 d. Double arrow-
heads indicate slight differences in the mobility of the three Akt isoforms 
detected by total and phospho-Akt antibodies and the mobility shift of 
IRS1. (B) Effect of Akt KD on xenograft tumor growth. Representative 
experiments showing the growth of PC3 xenograft tumors containing 
the various shRNAs treated with vehicle control (    Dox, closed circles) 
or Dox (+Dox, open circles; see Table S2, available at http://www.jcb
.org/cgi/content/full/jcb.200801099/DC1). Error bars represent SEM. 
*, P   <   0.05; **, P   <   0.005.     JCB • VOLUME 183 • NUMBER 1 • 2008  104 
somes (  Fig. 4 B  ;   Klionsky et al., 2008  ). The lysosomotropic 
agent chloroquine (CQ), a weak base amine widely used to in-
hibit the maturation of autophagosomes into degradative au-
tolysosomes (  Boya et al., 2005  ;   Kroemer and Jaattela, 2005  ; 
  Lum et al., 2005  ), caused the appearance of small GFP-LC3 clus-
ters in the perinuclear region. The combination of CQ with Akt 
KD resulted in a much stronger accumulation of GFP-LC3 dots 
as well as augmented accumulation of LC3-II in the presence of 
continued LC3-I turnover, consistent with a defect in autolyso-
somal degradation. Similar accumulation of MDC 
+   vacuoles was 
also observed (Fig. S2 F). This was accompanied by an acceler-
ated cell death in shAkt123-expressing cells treated with CQ 
under 0.5% and, more pronouncedly, 0% FBS (  Fig. 4, C and D  ). 
(unpublished data). Although the literature has been controversial 
on the effect of early stage autophagy inhibition on cell survival, 
blocking autophagy at a late stage has been more consistently 
shown to cause accelerated cell death under autophagy-inducing 
conditions (  Kanzawa et al., 2004  ;   Boya et al., 2005  ;   Gonzalez-Polo 
et al., 2005  ;   Kroemer and Jaattela, 2005  ;   Yu et al., 2006  ). There-
fore, we investigated the effect of blocking the completion of 
autophagy initiated by Akt KD on cell viability. In PC3-shAkt123 
cells stably expressing GFP-LC3, Akt KD resulted in punctate 
GFP signals ( Fig. 4 A  and Fig. S2 E) with a corresponding reduc-
tion of the nonlipidated precursor form of the endogenous LC3 
(LC3-I) and a slight increase in the lipidated autophagosome-
localized LC3-II, which is rapidly turned over in the autolyso-
  Figure 2.       Akt KD resulted in cell cycle delay without substantial apoptosis.   (A) Histological analysis of PC3-shAkt123 tumors treated with Dox or vehicle 
control for 5, 15, or 21 d as indicated. Tumor tissues were analyzed by IHC using antibodies speciﬁ  c for Ki-67 or by the TUNEL assay. Pathologist  ’  s 
scoring of the signal intensity for each sample is indicated in parentheses. Bars, 100   μ  m. (B and C) Effect of triple-Akt KD on cell cycle progression 
under serum starvation (ss) compared with cells grown under 10% FBS. Cells containing shRNAs targeting EGFP or all three Akts were pretreated for 
2 d with or without Dox in medium containing 10% FBS and changed to 0% (B) or 0.5% (C) FBS. Cell cycle proﬁ  les were analyzed at the indicated 
time points after serum withdrawal. Error bars represent SEM (  n   = 3). The percentage of change in each cell cycle phase with Dox versus without Dox 
treatment is also shown.     105  BLOCKING DEGRADATION KILLS AUTOPHAGIC CELLS   • Degtyarev et al. 
(  Fig. 4 B  ). In contrast, pretreatment with 1 mM 3-MA, an inhibi-
tor of the earliest stage of autophagosome formation, attributed 
to its inhibition of class III PI3K (  Seglen and Gordon, 1982  ; 
  Petiot et al., 2000  ), suppressed the cell death  –  promoting effect 
of either CQ or Ba on shAkt-expressing cells (  Fig. 4, C and D  ). 
This suggests that the accelerated cell death caused by the ly-
sosomotropic inhibitors is dependent on the accumulation of 
abnormal AVs. 
A second lysosomotropic agent, bafi  lomycin A1 (Ba), which in-
hibits the vacuolar proton pump (V-H 
+ -ATPase)  and  prevents 
the proper acidifi  cation of lysosomal compartments (  Yamamoto 
et al., 1998  ), also promoted cell death in combination with 
shAkt123. Increased annexin V  –  positive population and cas-
pase-3,7 activity was observed in cells treated with either CQ or 
Ba in combination with Akt KD, correlating with an increase 
in poly-ADP-ribose polymerase (PARP) cleavage in these cells 
  Figure 3.       Autophagy was induced in PC3 and 
U87MG cells by Akt KD.   (A) EM images of PC3 (a –  d) 
and U87MG (e  –  g) cells grown in the absence 
(a and f) or presence (b  –  e and g) of Dox-induced 
Akt123 KD for 5 d. Arrows, degradative autoly-
sosomes. Double arrows, initial AVs. Arrowhead, 
phagophore isolation membrane. M, mitochon-
drion in an AV. Asterisks, glycogen particle clusters. 
Bars: (a, b, f, and g) 0.5   μ  m; (c and d) 200 nm; 
(e) 1   μ  m. (B) Quantiﬁ  cation of the number of AVs 
per unit cytoplasmic area of 4.5   μ  m 
2   (  n     ≥   64) and 
the percentage of cytoplasmic area occupied by 
AV in randomly sampled cytoplasmic areas (  n   = 5 
areas of   >  200   μ  m 
2  ) of PC3 and U87MG cells with 
and without Dox-induced shAkt123 expression. Er-
ror bars represent SEM. (C) Dox-induced Akt si-
lencing caused degeneration in PC3 and U87MG 
tumors. (a) PC3 tumors expressing the control 
EGFP shRNA after 15 d of Dox treatment. The tu-
mor cells contain large nuclei and nucleoli, some 
lipid droplets (asterisks), and are connected by 
cell junctions (arrowheads). (b  –  d) PC3 tumors 
expressing shAkt123 after 15 (b and c) or 10 d 
(d) of Dox treatment. (b) Cells and nuclei in these 
tumors often appear shrunken. Arrows, AVs. E, 
eosinophil. (c) Two AVs (arrows) found among di-
lated RER cisternae in a degenerating tumor cell. 
(d) Ultrathin cryosection with immunogold labeling 
of human LAMP1. Label occurs on lysosomes (ar-
row) and AVs (top inset). Some of the tumor cells 
also contain human LAMP1  –  positive dense bod-
ies with a shape reminiscent of microautophagy 
(bottom inset;   de Waal et al., 1986  ). The tumor 
cells have widened nuclear envelope and ER cis-
terns (asterisks), which contain small cytoplasmic 
islands (arrowheads). (e) U87MG tumor after 
5 d of vehicle treatment. (f  –  h) U87MG-shAkt123 
tumor after 5 d of Dox treatment. Arrows, AVs. 
(h) In some tumor samples, cells with glycogen 
clusters (asterisks) and glycogen-containing AVs 
occur. Bars: (a  –  c) 2   μ  m; (e and f) 1   μ  m; (g) 0.5   μ  m; 
(d and h) 200 nm.     JCB • VOLUME 183 • NUMBER 1 • 2008  106 
In contrast to the broad-spectrum PI3K inhibitors wortmannin 
or LY294002, which are equipotent at inhibiting both class I 
and III PI3Ks and inhibit autophagy because of the latter ac-
tivity (  Petiot et al., 2000  ;   Knight et al., 2006  ), PI-103 is potent 
at inducing the accumulation of AVs (  Fig. 5, B and C  ). 
[ID]FIG5[/ID]  Similar 
to Akt KD, combination with CQ accelerated the death of cells 
treated with PI-103 (  Fig. 5 A  ). The markedly increased LC3-II 
to LC3-I ratio and the appearance of enlarged vacuoles brightly 
stained by MDC was observed before the detection of overt cell 
death (  Fig. 5, B and C  ). As observed with Akt KD, pretreatment 
with 3-MA reduced both LC3-II to -I ratios and the accumula-
tion of MDC 
+   vacuoles and slowed down the rate of cell death 
  CQ accelerated cell death in combination 
with PI3K and Akt inhibitors 
  Recently, a phosphatidylinositol ether lipid analogue that inhibits 
Akt activation was reported to induce autophagy with radiosensi-
tizing effect (  Fujiwara et al., 2007  ). Because phosphatidylinositol 
ether lipid analogues are known to have additional cellular targets 
( Gills et al., 2006 ;  Memmott et al., 2008 ), we asked whether other 
specifi  c inhibitors of PI3K  –  Akt could also induce autophagy and 
sensitize cells to late stage autophagy inhibition. We fi  rst used 
a dual PI3K/mTOR inhibitor, PI-103, which inhibits the class I 
PI3Ks and mTOR at nanomolar concentrations but is   >  1,000-
fold less potent on the class III PI3K (  Knight et al., 2006  ). 
  Figure 4.       Lysosomotropic agents accelerated cell death in combination with Akt KD.   (A) CQ treatment caused accumulation of GFP-LC3 dots in 
Dox-treated PC3-shAkt123 cells. PC3-shAkt123 cells stably expressing GFP-LC3 were pretreated with or without 1   μ  g/ml Dox for 6 d and treated 
with or without 10   μ  M CQ. GFP ﬂ  uorescence was imaged after 1 d of CQ treatment. Arrowheads point to representative GFP dots or clumps. Bar, 
10   μ  m. (B) Effect of shAkt123 and 10   μ  M CQ on LC3 processing, PARP cleavage, and total Akt in PC3-shAkt123 cells treated with or without Dox 
or CQ. The ratios of LC3-II to LC3-I and cleaved (Cl) to full-length (FL) PARP were quantiﬁ  ed from immunoblots of cell lysates made at days 1 and 2 
of CQ treatment. Immunoblots of day 2 samples are shown. Molecular masses are indicated in kilodaltons parenthetically next to each protein. 
Data are representative of three independent experiments. (C) CQ promoted cell death in PC3 cells induced to express shAkt123, whereas 3-MA 
pretreatment delayed this effect. PC3-shAkt123 cells were preincubated with 1   μ  g/ml Dox and/or 1 mM 3-MA for 3 d before 10   μ  M CQ or 2.5 nM 
Ba was added. Cell viability was determined at days 2, 3, and 4 under 0.5% (C) or 0% (D) FBS after CQ or Ba was added. The percentage of 
the annexin V  –  positive PI-negative population was determined at days 2, 3, and 4 under 0.5% FBS. Caspase-3/7 activity was determined at days 
2 and 3 under 0% FBS and expressed as relative ﬂ  uorescence units (RFU, in thousands) normalized to the same number of cells. Error bars represent 
SD of three independent experiments.     107  BLOCKING DEGRADATION KILLS AUTOPHAGIC CELLS   • Degtyarev et al. 
  Figure 5.       CQ accelerated cell death in combination with PI-103.   (A) PC3 cells were treated with DMSO or 0.5   μ  M PI-103 in the presence or absence of 
10   μ  M CQ under 0.5% FBS. Cell viability was determined by PI exclusion at days 2, 3, and 5. Annexin V staining was analyzed at days 2 and 3 and 
broken down into PI+ or PI     populations. (B) Time course of cell viability in PC3 cells treated with 0.5 (PI-103-0.5) or 20   μ  M (PI-103-20) PI-103 with or 
without 10   μ  M CQ or 3 mM 3-MA. PC3 cells pretreated with PI-103 for 24 h under 1% FBS were split into medium containing 0.5% FBS in the presence 
or absence of CQ. 3-MA was added immediately before PI-103, 24 h before CQ addition. Cell viability was determined by PI exclusion at the indicated 
time points after CQ addition. Error bars represent SEM (  n   = 3). LC3-II to LC3-I ratios were determined from quantitation of immunoblots (with 0.5   μ  M PI = 103. 
(C) CQ dramatically increased the size and number of MDC 
+   vacuoles in PC3 cells treated with PI-103, whereas 3-MA suppressed this effect. Cells were 
cultured in medium containing 0.5% FBS and treated with DMSO, 0.5   μ  M PI-103, 10   μ  M CQ, and 5 mM 3-MA, alone or in combinations as indicated. 
MDC staining at 48 h is shown. Bar, 10   μ  m.     JCB • VOLUME 183 • NUMBER 1 • 2008  108 
accumulation both contribute to the accelerated cell death in-
duced by CQ in combination with Akt inhibition. 
  Because autophagy is a key function of the lysosomal com-
partment (  Terman et al., 2006  ), we examined the lysosomal 
marker LAMP1 and cathepsin D, the predominant lysosomal as-
partic protease, by immunoblotting (  Fig. 6, B and C  ). Akti-1/2 
(  Fig. 5, B and C  ). In contrast, the cell death  –  promoting ef-
fect of CQ was partially mimicked by siRNA KD of LAMP2, 
a protein previously shown to be required for the maturation of 
autophagosomes into autolysosomes (Fig. S3, A and B, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200801099/DC1; 
  Gonzalez-Polo et al., 2005  ). 
  A similar effect of CQ was also obtained with a selective 
dual Akt1,2 inhibitor, Akti-1/2 (  Barnett et al., 2005  ). Treatment 
with Akti-1/2 alone effectively inhibited the phosphorylation 
of Akt on both Ser473 and Thr308 residues and signifi  cantly 
reduced the phosphorylation of downstream target S6 without 
causing signifi  cant cell death (  Fig. 6, A and B  ). 
[ID]FIG6[/ID]  Cotreatment 
with CQ resulted in a rapid drop in cell viability with com-
plete cell death observed by day 10. Immunoblot analysis re-
vealed a signifi  cant accumulation of LC3-II within 24 h of 
Akti-1/2 treatment, which is further enhanced upon CQ cotreat-
ment (  Fig. 6, B and C  ). 
  To follow the kinetics of cell death, we used time-lapse 
microscopy to image live cells treated with CQ and Akti-1/2 
(  Fig. 7 A   and Videos 1  –  4, available at http://www.jcb.org/cgi/
content/full/jcb.200801099/DC1). 
[ID]FIG7[/ID]  CQ treatment alone caused a 
mild decrease in cell division and a gradual accumulation of 
dark particles in the perinuclear region. AO staining indicates 
that these particles are AVOs whose formation is inhibited by 
3-MA (unpublished data). Treatment with Akti-1/2 alone resulted 
in near-complete inhibition of cell division without overt cell 
death. These cells exhibited a fl  attened morphology with accu-
mulation of AVOs that eventually fi  lled the cytoplasm. Cells 
treated with both Akti-1/2 and CQ showed similar accumulation 
of AVOs, but cell shrinkage and plasma membrane rupture was 
observed within 48 h. On a few occasions, two neighboring 
cells were found to form a membrane junction that expanded 
into complete fusion between the two cells before rupture of the 
plasma membrane (  Fig. 7 A  , white arrowheads; and Video 4). 
  Similar correlation between AVO accumulation and cell 
death was observed using multispectral imaging fl  ow cytometry 
(  Fig. 7, B and C  ). Treatment with either CQ or Akti-1/2 alone 
induced AVO accumulation without signifi  cant loss of viability, 
whereas the combination of both resulted in a further increase 
in AVO accumulation in live cells and a concomitant increase in 
cells with condensed apoptotic nuclei and the appearance of 
anucleated population characteristic of necrotic cells. 
  Autophagy inhibition and degradation-
defective autolysosome accumulation 
both contribute to accelerated cell death 
induced by CQ in combination with Akti-1/2 
  To investigate whether autophagy inhibition by itself is suffi  -
cient to induce accelerated cell death in combination with Akt 
inhibition, we used siRNA to KD Atg7, a gene involved in the 
formation of autophagosomes (  Ohsumi, 2001  ). KD of Atg7 
alone did not show a signifi  cant effect on cell death but induced 
a small drop in cell viability by day 3 when combined with 
Akti-1/2. However, when combined with both CQ and Akti-1/2, 
Atg7 KD resulted in a transient delay of cell death at day 2 (Fig. 
S3, C and D). Together with the aforementioned effect of 3-MA, 
these data suggest that autophagy inhibition and defective AV 
  Figure 6.       CQ accelerated cell death in combination with Akti-1/2.   
(A) PC3 cells were treated with DMSO or 4   μ  M Akti-1/2 in the presence 
or absence of 10   μ  M CQ under 0.5% FBS. Cell viability was determined 
by PI exclusion over the course of 10 d. Error bars represent SEM. Rep-
resentative data from one of three independent experiments are shown. 
(B) Immunoblot analysis of cell lysates collected at the indicated time points 
from the experiment shown in A. Arrowheads indicate the positions for 
LC3-I and -II, CathD 43, and CathD 28. Quantiﬁ  cations of the indicated 
markers are shown in C. CathD 43, the 43  –  50-kD forms of cathepsin D 
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after Akti treatment alone followed by an increase in the 28-kD 
heavy chain of the mature enzyme, again indicating an increased 
lysosomal activity. CQ caused accumulation of the precursor 
forms at the expense of the 28-kD chain, consistent with an in-
hibition of lysosomal cysteine protease activity required for the 
processing and maturation of cathepsin D (  Liaudet-Coopman 
et al., 2006  ). In cells treated with both Akti and CQ, the precursor 
forms of cathepsin D accumulated to even higher levels than ei-
ther alone, whereas the mature 28-kD chain decreased gradually. 
alone induced an increase in LAMP1 levels, consistent with an 
elevated lysosomal activity. Cathepsin D is synthesized as a 
43-kD preprocathepsin D that is cleaved cotranslationally and 
glycosylated to form a 46-kD procathepsin D, which is targeted 
to lysosomes yielding an intermediate that is further cleaved into 
a mature enzyme consisting of a 15- kD light chain and a 28-kD 
heavy chain. Using an antibody that detects both the 28-kD and 
the precursor forms of cathepsin D, an increase in the level of the 
premature forms of cathepsin D at 43  –  50 kD was fi  rst detected 
  Figure 7.       Accumulation of AVOs preceded plasma 
membrane rupture and correlated with the appear-
ance of apoptotic and anucleated cells with Akti-1/2 
and CQ treatment.   (A) PC3 cells treated with DMSO, 
10   μ  M Akti-1/2, 10   μ  M CQ, or both under 5% FBS 
were followed for 3 d using time-lapse microscopy. 
Representative images of the cells at the indicated time 
points are shown. White arrowheads indicate the fu-
sion between two adjacent cells before plasma mem-
brane rupture in cells treated with both agents. Full 
time-lapse videos are available in Videos 1  –  4, avail-
able at http://www.jcb.org/cgi/content/full/jcb
.200801099/DC1. Bar, 10   μ  m. (B) PC3 cells treated 
with the indicated agents were stained with AO and 
analyzed by multispectral imaging ﬂ  ow  cytometry. 
(left) Brightﬁ   eld (BF), nuclei (green), vacuoles (red), 
and green/red composite images of three representa-
tive cells with each treatment are shown. Bars, 10   μ  m. 
(middle) plotting AO green intensity versus AO green 
bright detail area revealed three distinct populations: 
R2 anucleated cells, R3 apoptotic cells, and R4 live 
cells. (right) AO red intensity for R4 is plotted on the 
histogram with an arbitrary gate (R5) drawn to include 
events with the brightest AO red intensity. R2, R3, and 
R4 histograms are overlaid in the Akti + CQ plot only. 
(C) Statistics for each population shown in B. *, percent-
age of total single cells; **, mean ﬂ  uorescence intensity 
of R4 live cells; ***, percentage of R4 live cells.     JCB • VOLUME 183 • NUMBER 1 • 2008  110 
enhanced the cell-killing effect of CQ when both are combined 
with Akti (Fig. S3 I). Similarly, pepstatin A, an inhibitor of as-
partic proteases including cathepsin D, also promoted cell death 
together with Akti-1/2 (Fig. S3 J). 
  CQ augmented Akti-induced mitochondrial 
superoxide and cellular reactive oxygen 
species (ROS) accumulation 
  Increasing evidence has suggested an intimate relationship between 
lysosomes and mitochondria in the execution of programmed 
cell death ( Bursch, 2001 ;  Terman et al., 2006 ). Therefore, we 
examined the effect of Akt inhibition and CQ on mitochondrial 
membrane potential. Consistent with Akt  ’  s function in main-
taining mitochondrial integrity (  Parcellier et al., 2008  ), Akti-1/2 
alone caused a decrease in mitochondrial membrane potential, 
although signifi  cant numbers of polarized mitochondria were 
still present in the majority of cells. Although CQ alone did not 
have a signifi  cant effect, cotreatment of CQ and Akti-1/2 caused 
an almost complete loss of mitochondrial potential, preceding 
the sharp drop in cell viability (Fig. S4, A and B, available at 
http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). 
  It has recently been reported that mitochondrial ROS is in-
volved in autophagy induction (  Scherz-Shouval et al., 2007  ). 
Because mitochondria are the primary intracellular source of 
superoxide (O  2  
.  
     ) generation, we analyzed O  2  
.  
      production  us-
ing MitoSOX red, an O  2  
.  
      indicator that accumulates in the mi-
tochondria as a function of membrane potential and fl  uoresces 
upon oxidation and subsequent binding to DNA. Akti-1/2 alone 
increased MitoSOX fl  uorescence within 6 h (  Fig. 8, A and C  ; and 
not depicted). 
[ID]FIG8[/ID]  Most of the fl  uorescence exhibited a mitochondrial 
localization pattern with a subpopulation of cells showing 
Akti treatment also reduced the level of p62, another marker 
of autophagic activity that is degraded in the autolysosomes 
(  Klionsky et al., 2008  ), whereas CQ blocked p62 degradation 
both with and without Akti treatment (Fig. S5 C, available at 
http://www.jcb.org/cgi/content/full/jcb.200801099/DC1). Collec-
tively, these data suggest that Akt inhibition causes an increased 
production and maturation of the lysosomal enzymes, whereas 
CQ cotreatment impairs the maturation of these enzymes in the fi  -
nal autolysosomal compartment, causing accumulation of de-
fective AVOs. The latter is accompanied by an increased cleavage 
of caspase 3 into the active forms within 2 d (  Fig. 6 B  ) with a cor-
responding increase in caspase activity and cleavage of its 
substrate PARP (unpublished data). zVAD.fmk, a pancaspase in-
hibitor, partially rescued cell death at all concentrations tested 
(Fig. S3 E). Although zVAD.fmk can also inhibit lysosomal cys-
teine proteases at higher concentrations, and the latter have been 
reported to mediate caspase-independent cell death (  Foghsgaard 
et al., 2001  ), neither of the broad-spectrum cysteine protease in-
hibitors zFA.fmk and ALLN (  N  -Acetyl-Leu-Leu-Nle-CHO) nor a 
more specifi  c cathepsin B inhibitor CA-074-Me showed signifi  -
cant rescue of cell death induced by Akti and CQ. Instead, the 
cysteine protease inhibitors enhanced cell killing in combination 
with Akti at 10  –  50   μ  M-concentrations, although they also showed 
cytotoxicity alone at higher concentrations (Fig. S3, F  –  H). These 
results suggest that cell death induced by Akti and CQ is at least 
partially caspase dependent, whereas lysosomal protease activity 
may be required for the survival of cells under Akt inhibition. 
  To further ask whether impaired lysosomal degradation 
can accelerate cell death in combination with Akt inhibition, we 
knocked down cathepsin D using siRNA. Indeed, this signifi  cantly 
increased cell death when combined with Akti-1/2 and further 
  Figure 8.       Akt inhibition induces mito-
chondrial superoxide and cellular ROS pro-
duction, which is augmented by CQ.   (A) PC3 
cells cultured in 0.5% FBS were treated with 
DMSO, 3   μ  M Akti-1/2, 10   μ  M CQ, or both, 
stained with MitoSOX red dye, and examined 
by ﬂ   uorescence microscopy. Images at 24 h 
are shown. Bar, 10   μ  m. (B) PC3 cells treated 
as in A were stained with the Image-iT LIVE 
green ROS Detection kit and examined by 
ﬂ  uorescence microscopy at 24 h. Bright ﬁ  eld 
(BF) images of cells are also shown. Bar, 10   μ  m. 
(C) Quantiﬁ  cation of MitoSOX red and ROS 
green ﬂ   uorescence intensities by ﬂ  ow  cytom-
etry at 24 h. Cells were treated as in A and B. 
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20% of the tumors throughout the study ( Fig. 9, C and D ). Similar 
results were obtained with a subcutaneous peritumor injection 
of CQ (unpublished data). EM examination of tumor samples 
taken at day 5 revealed a mild increase in the AV area in tumors 
treated with either Dox or CQ alone, whereas a dramatic accu-
mulation of AVs was observed in a tumor treated with both Dox 
and CQ that showed   >  50% regression. These AVs are larger than 
those found in the Dox- or CQ-alone tumors and contain dense 
undigested materials, but usually with a single-membrane auto-
lysosomal appearance and stained positive for human LAMP1, 
consistent with impaired degradation after autophagosome  –
  lysosome fusions. This coincides with an increased number of 
tumor nuclei exhibiting apoptotic morphology as well as AV-con-
taining cell debris with compromised plasma membrane integ-
rity and abnormal mitochondria (  Fig. 10   and not depicted). 
[ID]FIG10[/ID]  Thus, 
CQ not only accelerated cell death in combination with Akt 
inhibition in vitro but also increased the incidence of complete 
tumor remissions in vivo. 
  Discussion 
  Using a Dox-inducible shRNA approach, we specifi  cally 
knocked down each Akt isoform, both individually and in all 
possible combinations, to evaluate their requirement in the main-
tenance of tumor growth. Our results suggest that in the PTEN-
null PC3 and U87MG cells, Akt1 is the most important isoform, 
whereas Akt2 and Akt3 activities could partially compensate for 
the reduced Akt1 activity in maintaining tumor growth. Taking 
together both the potential metabolic side effects of Akt2 in-
hibition and the reported increase in invasiveness associated 
with inhibiting Akt1 alone that could be counteracted by simul-
taneous inhibition of Akt2 (  Irie et al., 2005  ), it may be necessary 
to inhibit two or all three Akt isoforms simultaneously to achieve 
maximum tumor inhibition, but with different degrees of in-
activation to preserve crucial levels of isoform activities to re-
duce side effects. 
  One of the most prominent functions of Akt is cell sur-
vival. Constitutively active Akt has been reported to protect 
cells from programmed cell death after various proapoptotic in-
sults (  Downward, 1998  ). However, whether apoptosis is a pri-
mary response to Akt inhibition is less clear, especially in cancer 
cells where apoptosis is often suppressed because of various 
genetic alterations. Previous experiments using small molecule 
inhibitors of the PI3K  –  Akt pathway often generate confl  icting 
results that are obscured by their nonspecifi  c effects. Our data 
indicate that specifi  c KD of Akt can cause cell cycle delay with-
out promoting signifi  cant apoptosis. This is consistent with a 
recent study that only a small portion of total Akt activity is re-
quired for apoptosis inhibition (  Liu et al., 2006  ). In contrast, we 
found that autophagy is a more sensitive response to reduced 
Akt activity caused by either specifi  c shRNA KD or selective 
inhibitors of the pathway. 
  Several mechanisms may contribute to autophagy induc-
tion by Akt inhibition. First, inhibiting Akt can lead to mTORC1 
inhibition. mTOR is a known inhibitor of autophagy. Interest-
ingly, a constitutively active form of Akt suppressed the induc-
tion of autophagy by rapamycin (  Takeuchi et al., 2005  ), raising 
nuclear fl  uorescence, consistent with increased mitochondrial 
permeability in these cells. Although CQ alone only caused a 
mild increase in MitoSOX signal, the combination with Akti-1/2 
resulted in a signifi  cant increase in fl  uorescence intensity with 
most cells exhibiting a strong nuclear staining pattern. The in-
crease in O  2  
.  
      production was followed by an increase in overall 
cellular ROS levels within 24 h, as measured using a general 
ROS-sensitive probe (  Fig. 8, B and C  ). Interestingly, cytoplas-
mic ROS signal induced by Akti-1/2 alone was attenuated within 
48 h, whereas cotreatment with CQ caused a prolonged increase 
in ROS levels (Fig. S4 D and not depicted). This is consistent 
with the notion that limited mitochondrial depolarization caused 
by Akt inhibition induces a transient ROS signal to increase 
autophagy, which in turn removes the damaged mitochondria. 
Impaired digestion of cellular components caused by CQ results 
in autolysosomal aggregation of deleterious oxidative products 
such as ceroid/lipofuscin, which can further amplify the ROS 
damage (  Moore et al., 2006  ), leading to cell death. 3-MA pre-
treatment reduced ROS levels induced by Akti (Fig. S4 C), sug-
gesting a class III PI3K dependence similar to starvation-induced 
ROS production (  Scherz-Shouval et al., 2007  ). Treatment with a 
general ROS scavenger   N  -acetylcysteine (NAC) rescued cell vi-
ability in the presence of Akti and CQ (Fig. S5, A and B). In ad-
dition, NAC reduced Akti-induced LC3 and GFP-LC3 lipidation, 
p62 degradation, and GFP-LC3 puncta formation (Fig. S5, 
C and D), consistent with an essential role of ROS in autophagy 
induction (  Scherz-Shouval et al., 2007  ). 
  CQ selectively accelerated cell death in 
Akti-treated PTEN-null cells in vitro and 
enhanced the antitumor efﬁ  cacy of Akt KD 
in vivo 
  Because PC3 cells are PTEN null, we explored whether PTEN 
status might affect the sensitivity of cells to Akt inhibition alone 
or in combination with CQ using isogenic PTEN 
+/+  and PTEN 
   /    
mouse embryonic fi  broblasts (MEFs). The PTEN 
   /     MEFs  were 
previously shown to have elevated Akt pathway activity and are 
more sensitive to the antiproliferative effect of mTOR inhibition 
than PTEN 
+/+   MEFs (  Sun et al., 1999  ). As shown in   Fig. 9 A  , the 
PTEN 
   /     MEFs were also significantly more sensitive to the 
cell-killing effect of combined CQ and Akti-1/2 than their PTEN 
+/+  
counterparts. 
[ID]FIG9[/ID]  This suggests that PTEN 
   /     cells  may be more 
dependent on autophagic degradation for survival upon Akt in-
hibition, raising the possibility that a reasonable therapeutic in-
dex may be achievable by selective targeting of the malignant 
PTEN-null tumor cells using this strategy. 
  To ask whether PTEN-null tumors also rely on autophagic 
degradation upon Akt inhibition in vivo, we examined the effect 
of CQ on the survival of PC3 xenograft tumors expressing 
shAkt123. As shown in   Fig. 9 B  , intraperitoneal injection of CQ 
alone caused a small but insignifi  cant reduction in tumor growth 
rate. Akt KD alone resulted in signifi  cant tumor growth in-
hibition with an initial tumor stasis, but most tumors failed to 
regress completely, and rebound occurred in 90% of the tumors 
within 2  –  3 wk; no complete remission was achieved. In con-
trast, complete regression was observed in 40% of the tumors 
treated with both Dox and CQ with stasis maintained in another JCB • VOLUME 183 • NUMBER 1 • 2008  112 
be accelerated through blocking autolysosomal degradation. 
Although autophagy may be a potential mechanism by which 
Akt inhibition restricts tumor growth, it may also provide tem-
porary relief from the metabolic and oxidative stress imposed 
by Akt inhibition. Inhibiting autophagy at an early stage may 
prevent this temporary protective effect but may also counteract 
its tumor inhibitory effect while allowing early escape via alter-
native survival mechanisms. Blocking lysosomal function af-
ter tumor cells have become committed and reliant on autophagic 
degradation, however, might avoid this counteracting effect 
while amplifying the oxidative damage and cytotoxic effects 
through accumulation of deleterious oxidative aggregates 
(  Seehafer and Pearce, 2006  ). Indeed, our data suggest that a com-
patible lysosomal degradation capacity is critical for cell survival 
in the presence of elevated autophagic activity induced by Akt 
inhibition such that inhibiting lysosomal function with lysosomo-
tropic agents, cathepsin D KD or lysosomal protease inhibitors, 
can all precipitate cell death in combination with Akt inhibition. 
the possibility that the effect of rapamycin on autophagy may be 
mediated at least partially through inhibiting Akt via its long-
term effect on mTORC2 (  Sarbassov et al., 2006  ). Second, other 
signaling outputs of Akt, such as the FoxO proteins (  Zhao et al., 
2008  ) or glucose metabolism, can also contribute to autophagy 
regulation independently of mTOR. Third, our data indicate that 
Akt inhibition induces increased mitochondrial superoxide and 
cellular ROS signals that can activate autophagy. 
  Autophagy activation may lead to eventual cell death 
when allowed to reach its limit or may sensitize cells to addi-
tional death-inducing stimuli either through eventual autopha-
gic cell death or switching to a more rapid death program such 
as apoptosis. For example, Akt inhibition may increase radio-
sensitivity through augmenting autophagic response (  Fujiwara 
et al., 2007  ), whereas calpain-mediated cleavage of Atg5 may 
switch autophagy into apotosis (  Yousefi   et al., 2006  ). Here we 
show that inhibiting Akt alone is ineffective in cell killing in the 
PTEN-null cancer cells that we examined, but cell death can 
  Figure 9.       CQ selectively accelerated cell 
death in Akti-treated PTEN-null cells in vitro 
and enhanced the antitumor efﬁ  cacy of Akt KD 
in vivo.   (A) PTEN 
    /      (    /    ) MEFs were more 
sensitive than isogenic PTEN 
+/+   (+/+) counter-
parts to the combined treatment with Akti-1/2 
and CQ. MEFs were treated with 5   μ  M each 
of Akti-1/2 and CQ under 1% FBS, and cell 
viability was determined at days 0, 2, and 
3 by PI exclusion. Error bars represent SEM 
(  n   = 3). (B) Mean tumor volumes of PC3 xeno-
graft tumors treated daily with vehicle (Veh), 
Dox only, CQ only, or both Dox and CQ over 
a 28-d period. The vehicle and vehicle + CQ 
groups were followed for up to 18 d before 
terminated because of weight loss from the tu-
mor burdens. Error bars represent SEM (  n   = 
10 tumors in each cohort). (C) Scatterplot of 
the tumor volumes in the Dox only and Dox + 
CQ groups on day 28 (P = 0.05). Horizontal 
bars indicate mean tumor volumes. Numbers 
of tumors with complete remission (CR, dashed 
line) are indicated for each group. (D) Indi-
vidual tumor growth plotted as a percentage 
of tumor volume change compared with day 0 
for the Dox only and Dox + CQ cohorts shown 
in B. Dashed lines indicate     100% change 
from the starting tumor volumes, i.e., complete 
tumor regression. Numbers of tumors with 
smaller (  <  0% change) or larger (  >  0% change) 
than the starting tumor volumes on day 28 
are indicated.     113  BLOCKING DEGRADATION KILLS AUTOPHAGIC CELLS   • Degtyarev et al. 
The MitoPT Mitochondrial Permeability Transition Detection kit was pur-
chased from Immunochemistry Technologies, LLC. 
  Inducible shRNA constructs and generation of inducible-shRNA clones 
  The pHUSH tetracycline-inducible retrovirus gene transfer vector has been de-
scribed previously (  Gray et al., 2005  ,  2007  ;   Hoeﬂ  ich et al., 2006  ). The com-
plementary double-stranded shRNA oligos were inserted into this vector 
system using a shuttle vector followed by a Gateway recombination reaction 
(Invitrogen) as previously described (  Grunwald et al., 2002  ). The shRNA se-
quences used in this study are summarized in Table S1. All constructs were 
veriﬁ  ed by sequencing. Retrovirus infection was performed as described pre-
viously (  Gray et al., 2005  ;   Hoeﬂ  ich et al., 2006  ). For single Akt isoform KDs, 
cells were infected with one retroviral vector encoding an shRNA construct 
singly targeting each Akt isoform (constructs 252 or 253 for Akt1, 254 or 
255 for Akt2, and 259 or 260 for Akt3), and stable clones were selected us-
ing 5   μ  g/ml puromycin. For dual Akt1 and Akt2 KD, a single shRNA target-
ing both Akt1 and 2 simultaneously (constructs 256 and 257) was used. Dual 
Akt2 and 3 (constructs 255 and 261) or triple Akt1, 2, and 3 (constructs 257 
and 261) KDs were achieved by coinfecting the cells with two retroviral vec-
tors containing different antibiotic selection markers (puromycin and hygro-
mycin), each encoding one single shRNA, and stable clones were selected 
using 5   μ  g/ml puromycin and 300   μ  g/ml hygromycin. For dual Akt1 and 
3 KD, either a single shRNA targeting both Akt1 and 3 (construct 258) or 
coinfection with two shRNA vectors (constructs 253 and 261) was used. 
  GFP-LC3 stable transfection 
  DNA construct containing human LC3B tagged at the N terminus with 
EGFP was transfected into PC3-shAkt123 and PC3 wild-type cells. Stable 
clones were selected using G418. 
  Immunoblot analysis, immunohistochemistry (IHC), and TUNEL assay 
  For immunoblot analysis, total protein lysates were subjected to SDS-PAGE 
and transferred to nitrocellulose. Antibodies used were anti-Akt1, anti  –  total-Akt, 
Autophagy, lysosomal changes, and oxidative stress have been 
associated with a lengthening list of anticancer treatments, and 
lysosomotropic agents have shown anticancer activity either alone 
or in combination with other therapeutic agents (  Shoemaker 
and Dagher, 1979  ;   Ohta et al., 1998  ;   Ostenfeld et al., 2005  ; 
  Amaravadi et al., 2007  ;   Carew et al., 2007  ;   Fujiwara et al., 
2007  ;   Groth-Pedersen et al., 2007  ). Here we report that autoph-
agy induced by Akt/PI3K/mTOR inhibition can also be exploited 
using lysosomotropic agents, such as the well-tolerated drug CQ, 
to promote the remission of PTEN-null human tumor xenografts. 
Because this effect is expected to correlate positively with the 
degree of autophagy induced by a given treatment, creative com-
bination of these agents with potent autophagy inducers, such as 
inhibitors of the Akt pathway, may profoundly affect their anti-
cancer effi  cacy. 
  Materials and methods 
  Cell culture and reagents 
  The PTEN 
    /      and PTEN 
+/+   MEFs were maintained as previously described 
(  Sun et al., 1999  ). The PC3 and U87MG cells were maintained at 37  °  C 
and 5% CO  2   in DME/Ham  ’  s F-12 (1:1) containing 10% tetracycline-free 
FBS (Invitrogen). Akti-1/2 was obtained from EMD (Akt inhibitor VIII;   Bar-
nett et al., 2005  ). To inhibit autophagy, cells were treated with 5  –  10   μ  M 
CQ, 2.5 nM Ba, or 1  –  5 mM 3-MA (all from Sigma-Aldrich) and analyzed 
at the indicated time points. MitoSOX red mitochondrial superoxide indicator 
and Image-iT LIVE Green ROS Detection kits were purchased from Invitrogen. 
  Figure 10.       Increased AV accumulation and 
apoptosis in PC3 tumor with combined Akt123 
KD and CQ treatment.   (A, a) EM images of 
PC3-shAkt123 tumors treated for 5 d with CQ 
only. Arrows, dense AVs and lysosomes; N, 
nucleolus. (b) Dox only. Arrows, AVs with a 
less dense appearance than in a. (c and d) 
Both Dox and CQ. (c) Numerous dense and 
enlarged AVs (arrows) accumulate in tumor 
cells. An apoptotic cell (Ap) is partially sur-
rounded by a macrophage (M). T, tumor cell. 
(d) Apoptotic nuclei (Ap) among the AV-loaded 
(arrows) tumor cells. Insets, enlarged images 
of AVs (a  –  c) and abnormal mitochondria (*) 
in each tumor. Bars: (a  –  c) 2   μ  m; (d) 1   μ  m. 
(B) Quantiﬁ   cation of the percentage of cyto-
plasmic area occupied by AVs in randomly 
sampled cytoplasmic areas (  n   = 6 areas of 
  >  80   μ  m 
2  ). (C) Percentage of apoptotic nuclei 
among randomly sampled tumor cell nuclei (  n   = 
3  –  4 sets of 100 tumor cell nuclei). (B and C) 
Error bars represent SEM; *, P   <   0.0005 com-
pared with the other three groups.     JCB • VOLUME 183 • NUMBER 1 • 2008  114 
After rinsing with PBS, the blocks were embedded in 12% gelatin, cryopro-
tected with 2.3 M sucrose, and frozen in liquid nitrogen. Ultrathin cryosec-
tions were cut at     120  °  C, picked up with 1% methylcellulose and 1.2 M 
sucrose, thawed, and collected on copper grids. After washing with PBS 
containing 0.02 M glycine, sections were incubated with rabbit anti  –
  human LAMP1 antibodies (provided by M. Fukuda, Burnham Institute for 
Medical Research, La Jolla, CA;   Carlsson et al., 1988  ) or with rat mono-
clonal anti  –  mouse LAMP1 antibody ID4B (provided by T. August, Develop-
mental Studies Hybridoma Bank, Iowa City, IA) followed by a secondary 
rabbit anti  –  rat IgG antibody (Dako). The sections were subsequently incu-
bated with protein A conjugated to 10-nm colloidal gold particles and con-
trasted with a 1.8% methylcellulose and 0.6% uranyl acetate mixture. 
  Cell viability and cell cycle analysis 
  Cell number and viability was measured using trypan blue exclusion assay 
using a Vi-Cell Analyzer (Beckman Coulter) or labeled with 1   μ  g/ml Prop-
idium iodide (PI) in PBS/1% BSA followed by cytoﬂ  uorometric  analysis 
with a ﬂ   uorescence-activated cell sorter (Becton Dickinson). FITC-conju-
gated annexin V was used for the assessment of phosphatidylserine expo-
sure by ﬂ  uorescence-activated cell sorter analysis. Caspase activation was 
analyzed using a Caspase-Glo 3/7 Assay kit (Promega). For cell cycle 
analysis, cells were ﬁ  xed with dropwise addition of chilled 70% ethanol, 
washed with PBS, and resuspended in staining solution containing 50   μ  g/ml 
PI and 60 U RNase A. DNA content was analyzed by ﬂ  ow cytometry using 
the FlowJo and ModFit software (Becton Dickinson). 
  Multispectral imaging ﬂ  ow cytometry 
  Cells treated with various agents were stained with 1   μ  g/ml AO and ana-
lyzed by the ImageStream system (Amnis Corporation) using the IDEAS im-
age analysis program. This allows quantitative characterization of single cells 
within a population by assessing a combination of morphology and ﬂ  uor-
escence patterns. AO ﬂ  uoresces green when bound to nuclei and red when 
concentrated in acidic vacuoles. The DNA AO green image and the vacuolar 
AO red image were ﬁ  rst compensated into separate channels, and the per-
centage of apoptotic/anucleate cells (based on AO nuclear morphology and 
intensity) and vacuolated cells (AO red+) were quantiﬁ  ed. Plotting AO green 
intensity versus the AO green bright detail area revealed three distinct popu-
lations: R2 anucleated cells (low AO green labeling and higher area caused 
by masking of diffuse cytoplasm), R3 apoptotic cells (intermediate to low AO 
green and very low AO green detail area caused by the presence of small, 
bright condensed nuclear fragments), and R4 live cells (intact bright nucleus). 
AO red intensity is plotted on the second histogram, with an arbitrary gate 
(R5) drawn to include events with the brightest AO red intensity. 
  Time-lapse video microscopy 
  Cells cultured in 24- or 96-well plates were imaged on an inverted micro-
scope (IX81; Olympus; or TE300; Nikon) equipped with environmental 
control (37  °  C and 5% CO  2  ) and a motorized X-Y stage. Images were 
taken with a CCD camera (HQ2 or Cascade 512; Photometrics) at 1-h in-
tervals with a 10  ×   objective with phase contrast for brightﬁ  eld or an FITC 
ﬁ  lter for GFP-LC3 ﬂ  uorescence. 
  Online supplemental material 
  Table S1 shows a summary of Akt shRNA oligos and constructs. Table 
S2 shows a summary of Akt KD efﬁ  ciency and effect on xenograft tumor 
growth for various PC3-Akt shRNA clones. Fig. S1 shows relative levels 
of Akt isoforms in cancer cell lines and inducible KD of Akt isoforms in 
U87MG cells and xenograft tumors. Fig. S2 shows the effect of GFP-targeting 
shRNA and Akt isoform KDs on cell cycle progression, apoptosis, and 
autophagy. Fig. S3 shows the effect of LAMP2, Atg7, protease inhibitors, 
cathepsin D siRNA, and pepstatin A on PC3 cell viability in combina-
tion with PI-103 or Akti-1/2. Fig. S4 shows CQ-promoted mitochondrial 
membrane depolarization and cellular ROS accumulation in combination 
with Akti-1/2. Fig. S5 shows NAC-rescued cell death induced by Akti + 
CQ. Video 1 is a time-lapse video of PC3 cells treated with DMSO con-
trol. Video 2 is a time-lapse video of PC3 cells treated with CQ alone. 
Video 3 is a time-lapse video of PC3 cells treated with Akti-1/2 alone. 
Video 4 is a time-lapse video of PC3 cells treated with both CQ and 
Akti-1/2. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200801099/DC1. 
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anti  –  p-Akt (Ser473), anti  –  p-Akt (Thr308), anti  –  p-S6 (Ser235/236), anti-PARP, 
and anticleaved caspase-3 (Cell Signaling Technology); anti-Akt2, anti-Akt3, 
and anti-IRS1 (Millipore); anti  –  p-PRAS40 and anti-GFP (Invitrogen); anti-p27 
Kip1   
(Santa Cruz Biotechnology, Inc.); anti-LC3 (Novus); anti-LAMP2 and anti  –  cathep-
sin D (BD Biosciences); anti-p62/SQSTM1 (BIOMOL International, L.P.); anti  –      -
actin (Sigma-Aldrich); and anti-glyceraldehyde-3-phosphate dehydrogenase 
(Advanced Immunochemical Inc.). Primary antibodies were detected using 
IR Dye 800  –  conjugated (Rockland) and Alexa Fluor 680  –  conjugated (Invitro-
gen) species-selective secondary antibodies. Detection and quantiﬁ  cation were 
performed using an infrared scanner (Odyssey; LICOR) using the manufacturer  ’  s 
software. For IHC, formalin-ﬁ  xed, parafﬁ  n-embedded specimens were collected. 
5-  μ  m-thick parafﬁ  n-embedded sections were stained using an anti  –  Ki-67 (MIB-1; 
Dako) antibody with the Animal Research Kit (Dako). Tissues were counter-
stained with hematoxylin, dehydrated, and mounted. In all cases, antigen re-
trieval was performed with the Target Retrieval kit (Dako) according to the 
manufacturer  ’  s instructions. For TUNEL assay, formalin-ﬁ  xed, parafﬁ  n-embedded 
sections were stained using an in situ cell death detection kit (POD; Roche) ac-
cording to the manufacturer  ’  s instructions. 
  Xenograft study 
  6  –  8-wk-old female athymic nude   nu/nu   mice were purchased from Charles 
River Laboratories and maintained in Genentech  ’  s conventional animal fa-
cility. Mice were injected in the right ﬂ   ank with 5  –  7.5   ×   10 
6   cells re-
suspended in 200   μ  l Hank  ’  s balanced salt solution (Invitrogen). When 
tumors reached a mean volume of 100  –  300 mm 
3  , the mice with similarly 
sized tumors were grouped into treatment cohorts. Mice received 5% su-
crose or 5% sucrose plus 1 mg/ml Dox in drinking water for control and 
KD cohorts, respectively. Amber-colored water bottles were used and were 
changed three times per week. CQ was dissolved in 0.9% physiological 
saline, ﬁ  lter sterilized, and administered at 45 mg/kg through either intra-
peritoneal or subcutaneous routes. Tumors were measured with calipers, 
and mice were weighed twice per week. Mice whose tumors reached 
2,000 mm 
3   or lost   >  20% body weight were killed. Between 8 and 10 mice 
were used for each treatment group. Statistical signiﬁ  cance was analyzed 
using JMP software (SAS Institute, Inc.). 
  Fluorescence microscopy 
  For LC3 immunoﬂ  uorescence staining, cells were ﬁ  xed in 3% paraformal-
dehyde and permeabilized with 0.01% digitonin in PBS followed by a 
rabbit polyclonal anti-LC3 (Abgent) primary antibody detected with 
a cy3-conjugated anti  –  rabbit secondary antibody (Jackson Immuno-
Research Laboratories). Cells were imaged by using a deconvolution 
microscopy system (DeltaVision; Applied Precision, LLC) built on an in-
verted microscope (IX-70; Olympus) with a Plan Apo 60  ×  /1.40 numeri-
cal aperture oil immersion objective lens and equipped with a ﬁ  lter set 
(Sedat Quad; Chroma Technology Corp.) with single-band excitation and 
emission ﬁ  lters, a high-resolution cooled charge-coupled device (CCD) 
camera (CH350; Roper Scientiﬁ  c), and SOFTWORX software (version 
2.5; Applied Precision, LLC). For labeling of AVs with MDC, cells were 
incubated with 0.05 mM MDC in PBS at 37  °  C for 10 min and immedi-
ately analyzed by ﬂ  uorescence microscopy using an inverted microscope 
(Eclipse TE 300; Nikon) equipped with a CCD camera (SPOT; Diagnostic 
Instruments, Inc.). 
  EM 
  Cells were grown to monolayer in plastic ﬂ  asks and ﬁ  xed in half-strength 
Karnovsky ﬁ  xative (2% paraformaldehyde, 2.5% glutaraldehyde, 0.025% 
CaCl  2  -2H  2  O, and 0.1 M sodium cacodylate buffer, pH 7.4), and tumors 
were cut into small cubes (    1 mm 
3  ) and ﬁ  xed by immersion in the same 
ﬁ  xative or in the ﬁ  xative used for immuno-EM. Cells and tissues were post-
ﬁ  xed with 1% OsO  4   and 1% K  4  Ru(II)(CN)  6   or 1.5% K  3  Fe(CN)  6  , dehydrated 
in ethanol, and embedded in epon. Ultrathin sections were stained with 
uranyl acetate and lead citrate. All EM sections were examined with a 
microscope (1200EX or 1010; Jeol). AVs, i.e., autophagosomes, amphi-
somes, and autolysosomes, were exclusively identiﬁ   ed by morphology. 
Numbers of AVs were counted on systematically sampled cytoplasmic ar-
eas of 4.5   μ  m 
2   (  n     ≥   64 per condition). The percentage of AV area was 
measured by means of a square mesh grid laid over at least ﬁ  ve sets of sys-
tematically sampled micrographs with each set covering a cytoplasmic 
area   ≥  80   μ  m 
2  . The mean percentage of apoptotic nuclei in tumor tissues 
was calculated from the number of apoptotic nuclei in three to four sets of 
100 systematically counted tumor cell nuclei. 
  Immuno-EM 
  Small tumor blocks were ﬁ  xed by immersion in 2% paraformaldehyde and 
0.2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, for 5 h at 4  °  C. 115  BLOCKING DEGRADATION KILLS AUTOPHAGIC CELLS   • Degtyarev et al. 
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